These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 33177386)

  • 21. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
    Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment.
    Hatanaka T; Kakizaki S; Nagashima T; Ueno T; Namikawa M; Tojima H; Takizawa D; Naganuma A; Arai H; Sato K; Harimoto N; Shirabe K; Uraoka T
    Acta Gastroenterol Belg; 2021; 84(1):65-72. PubMed ID: 33639695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
    Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
    Hiraoka A; Kumada T; Tada T; Tani J; Kariyama K; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Aoki T; Tanaka T; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Arai T; Okubo T; Imai M; Koizumi Y; Nakamura S; Joko K; Hiasa Y; Kudo M;
    Sci Rep; 2021 Aug; 11(1):16663. PubMed ID: 34404856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
    Zhao Y; Zhang YN; Wang KT; Chen L
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenvatinib: A Review in Hepatocellular Carcinoma.
    Al-Salama ZT; Syed YY; Scott LJ
    Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenvatinib
    Marrocco GA; Silletta M; Bianco V; Mondera F; Sciortino C; Pappalardo L; Viglialoro V; Cortesi E; Tonini G; Caponnetto S
    Anticancer Res; 2023 Feb; 43(2):755-763. PubMed ID: 36697101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.
    Choi NR; Kim JY; Hong JH; Hur MH; Cho H; Park MK; Kim J; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    BMC Gastroenterol; 2022 Mar; 22(1):135. PubMed ID: 35337274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
    Kim JJ; McFarlane T; Tully S; Wong WWL
    Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance of Lenvatinib in Hepatocellular Carcinoma.
    Guo J; Zhao J; Xu Q; Huang D
    Curr Cancer Drug Targets; 2022; 22(11):865-878. PubMed ID: 36267045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
    Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
    ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
    Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
    Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
    Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
    J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Hu L; Zheng Y; Lin J; Shi X; Wang A
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102061. PubMed ID: 36473632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice.
    Chen K; Wei W; Liu L; Deng ZJ; Li L; Liang XM; Guo PP; Qi LN; Zhang ZM; Gong WF; Huang S; Yuan WP; Ma L; Xiang BD; Li LQ; Zhong JH
    Cancer Immunol Immunother; 2022 May; 71(5):1063-1074. PubMed ID: 34559308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
    Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
    Sekiguchi S; Tsuchiya K; Yasui Y; Inada K; Kirino S; Yamashita K; Hayakawa Y; Osawa L; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Kurosaki M; Izumi N
    Cancer Rep (Hoboken); 2022 Nov; 5(11):e1613. PubMed ID: 35302279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
    Li X; Ding X; Li W; Chen J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1395-1403. PubMed ID: 36441192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.